行情

AGRX

AGRX

Agile
NASDAQ

实时行情|Nasdaq Last Sale

2.050
+0.040
+1.99%
已收盘, 19:56 03/27 EDT
开盘
1.950
昨收
2.010
最高
2.050
最低
1.860
成交量
148.90万
成交额
--
52周最高
4.765
52周最低
0.3500
市值
1.78亿
市盈率(TTM)
-5.3497
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测AGRX价格均价为7.80,最高价位9.00,最低价为6.00。

EPS

AGRX 新闻

更多
  • Week 14 MDA Breakout Forecast: Short-Term Picks To Give You An Edge
  • Seeking Alpha - Article · 1天前
  • Agile Therapeutics (AGRX) Stock Remains a Top Pick, Says Analyst
  • TipRanks · 6天前
  • Implied Volatility Surging for Agile Therapeutics (AGRX) Stock Options
  • Zacks · 03/18 13:49
  • Weekly CFO Buys Highlight
  • GuruFocus.com · 03/15 21:02

所属板块

制药
-0.41%
制药与医学研究
-0.87%

热门股票

代码
价格
涨跌幅

AGRX 简况

Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company's lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.
展开

微牛提供Agile Therapeutics Inc(NASDAQ-AGRX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的AGRX股票新闻,以帮助您做出投资决策。